围绕「抗坏血酸四异棕榈酸酯」与「舒缓」,本页收录 8 篇公开发表的学术文献(2006–2022 年):1 篇给出支持性数据,4 篇结论不一,2 篇未提供该指标的支持性数据,1 篇仅涉及作用机制,其中 3 篇为人体临床研究。以上为各原研究作者的结论,本平台不作再评价。
归类针对的是「单篇文献对某一项具体指标是否给出支持性数据」,不是对本成分的评价;结论均为原研究作者观点。
该研究评估含VC-IP的抗氧化配方对SDS诱导的皮肤炎症反应的影响,结果显示VC-IP配方减少了抗炎细胞因子释放并减轻了炎症体征,直接支持VC-IP的舒缓功效。
This study evaluates the effect of an antioxidant formulation containing VC-IP on SDS-induced skin inflammatory response, showing that the VC-IP formulation reduced anti-inflammatory cytokine release and alleviated inflammatory signs, directly supporting the soothing efficacy of VC-IP.
该研究评估含VC-IP和大米肽的防晒配方对年轻女性光老化的改善,结果显示增加皮肤水合和真皮回声,减少色素沉着,但配方为复合物,且未单独评估舒缓功效。
This study evaluates the improvement of photoaging in young women using a sunscreen formulation containing VC-IP and rice peptides, showing increased skin hydration and dermal echogenicity, and reduced pigmentation, but the formulation is a complex mixture and does not separately evaluate soothing efficacy.
该研究评估含褪黑素、补骨脂酚和VC-IP的复合精华的抗衰老功效,结果显示减少皱纹、增加紧致度、降低红斑,但配方为多种活性物组合,无法单独证明VC-IP的舒缓功效。
This study evaluates the anti-aging efficacy of a complex serum containing melatonin, bakuchiol, and VC-IP, showing reduced wrinkles, increased firmness, and decreased erythema, but the formulation is a combination of multiple active ingredients, so the soothing efficacy of VC-IP cannot be proven alone.
该研究主要评估防晒剂对维生素A、C、E衍生物的光稳定性和功效的影响,未直接测试VC-IP的舒缓功效;结果显示含维生素的配方(包括VC-IP)增加了表皮厚度和TEWL,但未提及舒缓相关指标(如红斑、炎症),且配方中同时含有其他活性物,无法单独归因于VC-IP。
This study mainly evaluates the effect of sunscreens on the photostability and efficacy of vitamins A, C, and E derivatives, and does not directly test the soothing efficacy of VC-IP; results show that vitamin-containing formulations (including VC-IP) increased epidermal thickness and TEWL, but no soothing-related indicators (e.g., erythema, inflammation) were mentioned, and the formulation contains other active ingredients, so the effect cannot be solely attributed to VC-IP.
该研究评估黄酮类与维生素(包括VC-IP)组合的抗氧化和光保护作用,结果显示减少晒伤细胞数,但红斑和TEWL未显著改善,且为复合配方,无法单独证明VC-IP的舒缓功效。
This study evaluates the antioxidant and photoprotective effects of a combination of flavonoids and vitamins (including VC-IP), showing a reduction in sunburn cell count, but erythema and TEWL were not significantly improved, and it is a complex formulation, so the soothing efficacy of VC-IP cannot be proven alone.
该研究仅评估VC-IP在配方中的化学稳定性,未涉及任何舒缓功效或生物学效应。
This study only evaluates the chemical stability of VC-IP in formulations, without involving any soothing efficacy or biological effects.
该研究评估超声联合微泡增强VC-IP透皮递送的美白效果,未涉及舒缓功效;虽然提到皮肤未受损,但未测量舒缓相关指标。
This study evaluates the whitening effect of ultrasound combined with microbubbles to enhance transdermal delivery of VC-IP, without involving soothing efficacy; although it mentions that the skin was not damaged, no soothing-related indicators were measured.
该研究评估VC-IP等维生素C衍生物对胶原蛋白产生的影响,未涉及舒缓功效。
This study evaluates the effect of vitamin C derivatives including VC-IP on collagen production, without involving soothing efficacy.
篇数为本站收录的公开文献数,不同功效之间不可直接比较强弱 —— 研究热度受行业投入影响,与成分实际表现无关。
排序依据是本站收录的公开文献篇数,只反映研究数量、不代表功效强弱,也不是选料建议。
本站收录 8 篇与「舒缓」相关的公开发表研究,年份跨度 2006–2022;其中人体临床研究 3 篇。逐篇的研究类型与结论解读见本页「文献逐条」。
不能。中国现行法规要求功效宣称依据按《化妆品功效宣称评价规范》以人体功效评价试验、消费者使用测试或实验室试验等规定方式取得,文献综述仅在特定情形下可用。本页只是公开文献的整理,不构成宣称依据。
按原研究作者自身的结论归类:支持 1 篇、结论不一 4 篇、未观察到效果或结论相反 2 篇、仅机制探讨 1 篇。结论不完全一致,阅读时请结合各研究的研究类型与试验条件。
国家药监局备案数据中,含抗坏血酸四异棕榈酸酯且宣称「舒缓」的产品有 4,458 个,占该成分全部备案产品的 19.25%,相对全市场的富集度 lift 为 2.206。共现是市场统计上的相关性,不代表该成分对该功效有贡献。
是否收录于《已使用化妆品原料目录》、以及各法域的限量与使用范围,见抗坏血酸四异棕榈酸酯的成分档案页;本页只整理与「舒缓」相关的文献证据,不含法规限值。